Skip to content
Apex Nursing

Guide — Endocrine

Hypoglycemia Management

Classification by severity, causes, adrenergic and neuroglycopenic symptoms, Rule of 15, severe hypoglycemia protocols, Somogyi effect vs dawn phenomenon, hypoglycemia unawareness, and patient education.

9 min read · Endocrine

Educational use only. Hypoglycemia treatment protocols vary by institution. Always follow facility-specific protocols and provider orders. Severe hypoglycemia is a medical emergency. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.

Classification by Severity

LevelGlucoseSymptomsTreatment
Level 1 (Alert value)< 70 mg/dLAdrenergic symptoms: tremor, diaphoresis, tachycardia, palpitations, anxiety, hunger — patient is conscious and alertRule of 15 (15g fast-acting carbs); recheck in 15 min
Level 2 (Clinically significant)< 54 mg/dLNeuroglycopenic symptoms add: confusion, difficulty concentrating, behavior change, blurred vision, headache, weaknessRule of 15 if conscious and able to swallow; IV dextrose if unable to swallow safely
Level 3 (Severe)Any level with severe cognitive impairmentSeizure, loss of consciousness, unresponsiveness — patient requires assistance from another personD50W IV (preferred if IV access) or glucagon IM/SQ; do NOT give oral glucose to unconscious patient

Common Causes

CauseMechanism / Clinical Note
Insulin excess (most common)Too much insulin (absolute or relative), wrong type, poor timing relative to meals
Sulfonylureas / MeglitinidesStimulate insulin secretion regardless of glucose level; high hypoglycemia risk especially when meal is delayed or skipped
Delayed or missed mealInsulin on board without adequate glucose substrate
Alcohol consumptionInhibits hepatic gluconeogenesis; mask hypoglycemia symptoms by mimicking intoxication
Strenuous exerciseIncreases glucose utilization; effect can persist hours after exercise
Renal/hepatic failureImpaired insulin degradation (kidneys) and impaired gluconeogenesis (liver) prolong and worsen hypoglycemia
Drug interactionsBeta-blockers mask adrenergic symptoms (tachycardia, tremor) — patient may present directly with neuroglycopenic symptoms
Adrenal insufficiencyCortisol is a counter-regulatory hormone — its absence blunts glucose recovery

Rule of 15 — Mild to Moderate Hypoglycemia

Step-by-Step Protocol

  1. Confirm glucose < 70 mg/dL via glucometer
  2. Administer 15 grams of fast-acting carbohydrates orally
  3. Wait 15 minutes
  4. Recheck blood glucose
  5. If glucose still < 70 mg/dL: repeat 15g carbs and wait 15 min
  6. If glucose > 70 mg/dL and meal not imminent: give small snack containing protein + complex carb (e.g., peanut butter crackers) to prevent rebound
  7. Notify provider and document

15g Fast-Acting Carbohydrate Options

4 oz (½ cup) orange juice or apple juice
4 oz (½ cup) regular (non-diet) soda
3–4 glucose tablets (4g each)
1 tablespoon honey or sugar
1 small tube glucose gel
8 oz (1 cup) low-fat milk

Avoid: chocolate, peanut butter, high-fat foods — fat delays glucose absorption and slows treatment response

Severe Hypoglycemia — Emergency Treatment

TreatmentRouteDoseNotes
D50W (50% dextrose)IV (preferred)25g (50 mL of D50W) — per orderFastest onset; requires IV access; give slowly — vesicant, causes vein damage if extravasates; recheck glucose in 15 min
Glucagon kitIM or SQ (when no IV access)1 mg (adults); 0.5 mg (children < 20 kg)Stimulates hepatic glycogenolysis; requires glycogen stores (may be ineffective in malnourished, alcoholics, or prolonged hypoglycemia); onset 10–15 min; causes nausea/vomiting — position patient laterally
Nasal glucagon (Baqsimi)Intranasal3 mg (one nasal spray)Newer formulation; no mixing required; approved for community/outpatient use; same mechanism as IM glucagon

Critical Safety Points

  • NEVER give oral glucose to an unconscious or seizing patient — aspiration risk
  • After D50W or glucagon, give follow-up carbohydrates + protein to prevent rebound hypoglycemia
  • Notify provider after any severe hypoglycemia — insulin regimen review required
  • Document: time detected, glucose value, treatment given, time of recheck, glucose after treatment, patient response, provider notified

Somogyi Effect vs Dawn Phenomenon

FeatureSomogyi Effect (Rebound Hyperglycemia)Dawn Phenomenon
CauseNocturnal hypoglycemia (2–3am) triggers counter-regulatory hormones (glucagon, cortisol, epinephrine) → rebound hyperglycemia by morningNormal physiologic rise in growth hormone and cortisol in early morning (4–8am) → hepatic glucose release and insulin resistance → fasting hyperglycemia
2–3am glucoseLow (hypoglycemic)Normal or slightly elevated
Fasting AM glucoseHigh (rebound from nocturnal hypo)High
TreatmentREDUCE evening/bedtime insulin dose — increasing insulin worsens nocturnal hypoglycemiaINCREASE basal insulin dose or adjust timing; early AM snack may help in some cases
How to differentiateCheck 2–3am glucose: LOW = Somogyi (reduce PM insulin). NORMAL/HIGH = Dawn phenomenon (increase basal or add coverage).

Hypoglycemia Unawareness

Definition: Inability to recognize hypoglycemia symptoms until glucose is severely low — patients skip adrenergic warning signs and present directly with neuroglycopenic symptoms (confusion, loss of consciousness).

Cause: Occurs after frequent hypoglycemic episodes — the counter-regulatory hormone response becomes blunted; beta-blockers can mask adrenergic symptoms even in people without unawareness.

Risk factors: Long-standing Type 1 DM, frequent hypoglycemia, autonomic neuropathy, beta-blocker use, elderly patients.

Nursing implications:

  • More frequent glucose monitoring (CGM is ideal)
  • Higher glucose target thresholds for these patients
  • Educate family/caregivers on how to administer glucagon
  • Educate patient to check glucose before driving
  • Inform provider — insulin regimen adjustment may be warranted

NCLEX Pearls

Treat first, notify second: Glucose < 50 with symptoms = treat immediately (D50W or Rule of 15), then notify provider. Do NOT wait for an order to treat severe symptomatic hypoglycemia — nurses have standing orders for this.

Unconscious patient: IV D50W preferred; if no IV access, glucagon IM or nasal. NEVER oral glucose — aspiration.

Beta-blockers mask hypoglycemia: Patients on beta-blockers may not show tachycardia or tremor — diaphoresis is NOT masked and remains a reliable sign. More frequent monitoring needed.

Somogyi = reduce PM insulin: High morning glucose with low 2–3am glucose = rebound. Do NOT increase insulin — reduce it.

Glucagon requires glycogen stores: Will be ineffective in malnourished, prolonged fasting, alcoholic, or liver failure patients — use D50W instead.

Follow-up snack after treatment: After glucose rises above 70 mg/dL, give protein + complex carb snack if next meal is > 1 hour away — prevents rebound hypoglycemia from treatment.

Related Resources

Standards & sources

Fact-checked Jun 20, 2026

This page is written to align with American Diabetes Association (ADA) Standards of Care · American Association of Clinical Endocrinology (AACE). It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →